X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1305) 1305
Publication (114) 114
Book Review (20) 20
Book Chapter (10) 10
Conference Proceeding (3) 3
Newspaper Article (2) 2
Book / eBook (1) 1
Dissertation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (959) 959
female (605) 605
male (602) 602
index medicus (567) 567
octreotide (555) 555
middle aged (520) 520
endocrinology & metabolism (519) 519
octreotide - therapeutic use (488) 488
adult (465) 465
aged (366) 366
acromegaly - drug therapy (357) 357
somatostatin - analogs & derivatives (348) 348
acromegaly (330) 330
treatment outcome (297) 297
octreotide - administration & dosage (245) 245
somatostatin (236) 236
somatostatin - therapeutic use (235) 235
antineoplastic agents, hormonal - therapeutic use (213) 213
oncology (203) 203
somatostatin analogs (199) 199
tumors (197) 197
therapy (195) 195
neuroendocrine tumors (190) 190
management (182) 182
delayed-action preparations (168) 168
octreotide lar (159) 159
lanreotide (151) 151
insulin-like growth factor i - metabolism (148) 148
efficacy (147) 147
growth-hormone (144) 144
medicine & public health (143) 143
neuroendocrine tumors - drug therapy (134) 134
octreotide - adverse effects (128) 128
human growth hormone - blood (124) 124
peptides, cyclic - therapeutic use (122) 122
care and treatment (114) 114
pharmacology & pharmacy (114) 114
aged, 80 and over (113) 113
adenoma - drug therapy (112) 112
acromegaly - blood (111) 111
pituitary neoplasms - drug therapy (105) 105
surgery (105) 105
cancer (102) 102
octreotide-lar (101) 101
diagnosis (97) 97
diabetes (96) 96
growth hormone (93) 93
follow-up (92) 92
antineoplastic agents - therapeutic use (91) 91
gastroenterology & hepatology (90) 90
somatostatin - administration & dosage (89) 89
animals (88) 88
growth-factor-i (88) 88
retrospective studies (88) 88
somatostatin analog (88) 88
prospective studies (86) 86
multicenter (84) 84
endocrinology (83) 83
octreotide - pharmacology (83) 83
research (82) 82
expression (81) 81
antineoplastic agents, hormonal - administration & dosage (80) 80
insulin-like growth factor i - analysis (80) 80
everolimus (77) 77
patients (77) 77
receptors, somatostatin - metabolism (76) 76
magnetic resonance imaging (75) 75
secreting pituitary-adenomas (74) 74
health aspects (73) 73
igf-i (73) 73
acromegaly - surgery (71) 71
mortality (71) 71
quality of life (71) 71
neuroendocrine tumors - pathology (70) 70
pegvisomant (70) 70
drug therapy (68) 68
follow-up studies (68) 68
long-term treatment (68) 68
pancreatic neoplasms - drug therapy (68) 68
somatostatin - adverse effects (68) 68
young adult (67) 67
somatostatin analogues (66) 66
time factors (66) 66
acromegaly - etiology (65) 65
acromegaly - metabolism (65) 65
chemotherapy (65) 65
metastasis (65) 65
pituitary neoplasms - pathology (65) 65
tumor shrinkage (65) 65
abridged index medicus (64) 64
octreotide acetate (63) 63
medicine (62) 62
transsphenoidal surgery (62) 62
adolescent (61) 61
slow-release lanreotide (59) 59
human growth hormone - analogs & derivatives (58) 58
medicine, general & internal (58) 58
neuroendocrine tumor (58) 58
pituitary-adenomas (58) 58
somatostatin receptors (58) 58
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1236) 1236
Spanish (14) 14
Japanese (11) 11
Portuguese (10) 10
Korean (9) 9
Polish (7) 7
German (6) 6
French (5) 5
Hungarian (5) 5
Italian (4) 4
Czech (3) 3
Chinese (2) 2
Danish (1) 1
Turkish (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Endocrinology, ISSN 0300-0664, 06/2007, Volume 66, Issue 6, pp. 859 - 868
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 09/2015, Volume 80, Issue 3, pp. 460 - 472
Journal Article
Journal Article
Endocrine - Related Cancer, ISSN 1351-0088, 10/2012, Volume 19, Issue 5, pp. 657 - 666
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 06/2019, Volume 104, Issue 6, pp. 1978 - 1988
Context: Pasireotide long-acting release (LAR) is a somatostatin multireceptor ligand, and in the current consensus criteria pasireotide LAR is considered the... 
SOMATOSTATIN ANALOG SOM230 | IN-VITRO | PEGVISOMANT | LONG-ACTING OCTREOTIDE | SAFETY | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | CLINICAL-PRACTICE | LANREOTIDE | PITUITARY-ADENOMAS | 120 MG
Journal Article
The Oncologist, ISSN 1083-7159, 09/2014, Volume 19, Issue 9, pp. 930 - 936
摘要 背景。 奥曲肽 LAR 用于控制类癌综合征 (CS) 及其他激素分泌过多症状的患者。 本研究的目的是在三个癌症转诊中心接受奥曲肽 LAR 剂量递增治疗的神经内分泌肿瘤 (NET) 患者中探讨奥曲肽 LAR 剂量递增的原因,并观察 CS 症状改善情况。 方法。 回顾了确诊患有类癌或胰腺 NET 并于... 
Somatostatin analogs | Diarrhea | Flushing | Carcinoid syndrome symptoms | Neuroendocrine tumor | Above‐standard dose | Above-standard dose | MANAGEMENT | ONCOLOGY | GUIDELINES | Neuroendocrine Tumors - pathology | Humans | Middle Aged | Neuroendocrine Tumors - complications | Octreotide - adverse effects | Male | Malignant Carcinoid Syndrome - complications | Malignant Carcinoid Syndrome - pathology | Diarrhea - chemically induced | Drug-Related Side Effects and Adverse Reactions - pathology | Malignant Carcinoid Syndrome - drug therapy | Neuroendocrine Tumors - drug therapy | Female | Aged | Octreotide - administration & dosage | Gastrointestinal Cancer
Journal Article
Journal Article
PLoS medicine, ISSN 1549-1277, 04/2019, Volume 16, Issue 4, p. e1002777
Journal Article
The Oncologist, ISSN 1083-7159, 03/2016, Volume 21, Issue 3, pp. 308 - 313
摘要 引言 . 长效释放奥曲肽 (奥曲肽 LAR) 获批用于治疗类癌综合征, 可能改善高分化神经内分泌肿瘤 (NET) 患者的无进展生存。但尚不明确奥曲肽 LAR 的剂量是否会影响生存。本文评价了奥曲肽 LAR 起始剂量与老年 NET 患者总生存之间的相关性。 患者与方法 . 从监测、流行病学和最终结果 (SEER)... 
Malignant carcinoid syndrome | Somatostatin analogue | SEER‐Medicare | Neuroendocrine tumors | SEER-Medicare | ONCOLOGY | CARCINOID-SYNDROME | CLINICAL COMORBIDITY INDEX | Multivariate Analysis | Humans | Kaplan-Meier Estimate | Proportional Hazards Models | Male | Treatment Outcome | Octreotide - therapeutic use | Dose-Response Relationship, Drug | Disease-Free Survival | Antineoplastic Agents, Hormonal - therapeutic use | Aged, 80 and over | Neuroendocrine Tumors - drug therapy | Female | Aged | Retrospective Studies | Gastrointestinal Cancer
Journal Article